Where to Inject a GLP-1: Abdomen, Thigh or Arm, According to Each Label
Where to inject a GLP-1 is answered the same way on every currently marketed brand-name, single-agent FDA label for an injectable GLP-1 receptor agonist: subcutaneously, in the abdomen, thigh or upper arm, rotating the site with each dose. That sentence sits in Section 2 of the prescribing information for Ozempic and Wegovy (semaglutide, Novo Nordisk), Mounjaro and Zepbound (tirzepatide, Eli Lilly), Saxenda and Victoza (liraglutide, Novo Nordisk) and Trulicity (dulaglutide, Eli Lilly). Section 12.3 of the Ozempic, Wegovy, Mounjaro and Zepbound labels states that similar exposure was achieved in the abdomen, thigh or upper arm; Trulicity states the site had no statistically significant effect on exposure; the liraglutide labels call exposure across the three sites comparable. The one difference is the upper arm, and it splits by document layer rather than by manufacturer: Section 2 of the Mounjaro and Zepbound labels says another person should inject it, the Novo Nordisk Section 2 text does not, and the Instructions for Use on both sides — the Lilly pens, the Victoza pen and the Ozempic and Wegovy prefilled syringes — condition the upper arm on help from another person. Every quotation below names the label, the section and the access date. This is a transcription of public labeling, not medical advice; which site you use is between you and your prescriber.
· Educational content — not medically reviewed
The short answer
Where to inject a GLP-1 is stated identically on every brand-name, single-agent FDA label for an injectable GLP-1 receptor agonist: subcutaneously in the abdomen, thigh or upper arm, rotating sites with each dose. Section 12.3 of the Ozempic, Wegovy, Mounjaro and Zepbound labels states similar exposure across all three sites; Trulicity reports no significant site effect. Mounjaro and Zepbound Section 2 adds that another person should inject the back of the upper arm.
Key takeaways
- All seven brand-name, single-agent injectable GLP-1 labels currently marketed in the United States — Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity — name the same three areas in Section 2: abdomen, thigh and upper arm, always subcutaneously (accessed 14 September 2026).
- Every label says to rotate. Wegovy, Mounjaro, Zepbound and Trulicity print "Rotate injection sites with each dose"; Ozempic says "use a different injection site each week when injecting in the same body region"; Saxenda and Victoza say to rotate "within the same region in order to reduce the risk of cutaneous amyloidosis".
- Absorption does not meaningfully differ by site, per the labels. Section 12.3 of the Ozempic, Wegovy, Mounjaro and Zepbound labels each states that similar exposure was achieved in the abdomen, thigh or upper arm (Ozempic puts it in the present tense: "is achieved"). Trulicity: the site "had no statistically significant effect on the exposure to dulaglutide." Victoza reports thigh AUC 22% lower than abdomen and still calls the three sites "comparable".
- Only the Mounjaro and Zepbound Section 2 text assigns the upper arm to another person: both print "another person should inject in the back of the upper arm", while Section 2 of the Novo Nordisk labels, and Trulicity's Section 2.4, list the upper arm without that condition. In the Instructions for Use the condition appears on both sides: the Lilly pen IFUs, the Victoza pen IFU ("only if caregiver administered") and the Ozempic and Wegovy prefilled-syringe IFUs ("only with help from someone else").
- The Instructions for Use separate the same area from the same spot. Wegovy IFU: "You may inject in the same body area each week, but make sure it is not in the same spot each time." Mounjaro, Zepbound and Trulicity IFUs: "You may use the same area of your body but be sure to choose a different injection site in that area."
Three areas, one sentence, every label
Ozempic: "Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm." Wegovy, Saxenda, Victoza and Trulicity use the same three words in the same order. Mounjaro and Zepbound: "in the abdomen, thigh, or have another person inject ... in the back of the upper arm" (Section 2 of each label, accessed 14 September 2026).
Rotate: the instruction that is never absent
Four labels print the bullet "Rotate injection sites with each dose." Ozempic phrases it as a different site each week within the same region. Saxenda and Victoza give a reason no other label gives — cutaneous amyloidosis — and cross-reference their own Section 6.2.
Absorption by site, as Section 12.3 states it
Ozempic, Wegovy, Mounjaro and Zepbound each say similar exposure was achieved in the abdomen, thigh or upper arm. Trulicity says site had no statistically significant effect. Victoza is the most detailed: thigh AUC 22% lower than abdomen, exposures still considered comparable (Section 12.3 of each label, accessed 14 September 2026).
The upper arm is the only place the labels disagree
In Section 2, Lilly's Mounjaro and Zepbound text says another person should give an upper-arm injection, and Novo Nordisk's Section 2 for Ozempic, Wegovy, Saxenda and Victoza lists the upper arm without that condition. In the Instructions for Use the line no longer follows the manufacturer: the Lilly pen IFUs, the Victoza pen IFU and the Ozempic and Wegovy prefilled-syringe IFUs all condition the upper arm on another person (Section 2 and IFU of each label, accessed 14 September 2026).
The short answer: three areas on every label, and where each label says it
Every brand-name, single-agent injectable GLP-1 receptor agonist is labeled for subcutaneous injection in three areas — the abdomen, the thigh and the upper arm — and every label tells the prescriber to have the patient rotate sites. That covers the seven brand-name products currently marketed in the United States: Ozempic (semaglutide injection, Novo Nordisk, label revised 05/2026), Wegovy (semaglutide injection, Novo Nordisk, revised 06/2026), Mounjaro (tirzepatide, Eli Lilly, revised 08/2026), Zepbound (tirzepatide, Eli Lilly, revised 08/2026), Saxenda (liraglutide, Novo Nordisk, revised 06/2026), Victoza (liraglutide, Novo Nordisk, revised 10/2025) and Trulicity (dulaglutide, Eli Lilly, revised 03/2026). An eighth label, Bydureon BCise (exenatide extended-release, AstraZeneca, revised 05/2025), says the same three areas; Drugs@FDA lists NDA 209210 as discontinued and the product no longer appears on DailyMed, so it is quoted here from FDA accessdata as a matter of record. Byetta (exenatide injection, AstraZeneca, NDA 021773) still appears on DailyMed, but Drugs@FDA lists it as discontinued, so it is not quoted. Two groups of labels are deliberately left out. DailyMed (accessed 14 September 2026) also lists generic liraglutide injection from labelers including Teva, Hikma, Lupin, Biocon, Cipla, Meitheal, NorthStar, Hybio and Orbicular, and a generic exenatide injection from Amneal; as generics, those labels reproduce the Victoza, Saxenda and Byetta wording and are not quoted separately. The insulin combination products Xultophy 100/3.6 (insulin degludec and liraglutide, Novo Nordisk) and Soliqua 100/33 (insulin glargine and lixisenatide, Sanofi) are outside this page's scope.
The instruction lives in the same place on every label: Section 2, Dosage and Administration, in a short bulleted subsection on administration. The three areas are repeated in the Medication Guide that comes with each pen, and again in the step-by-step Instructions for Use (IFU) beside a body diagram. This page quotes all three layers, because they do not say quite the same thing.
Each quotation names the label, the section and the date it was read (accessed 14 September 2026). Where a label is silent, the page says so rather than filling the gap. It adds no technique or site advice of its own; those belong to the prescriber, the pharmacist and the IFU, and the how to rotate GLP-1 injection sites page covers the record-keeping side of the same question.
- 1Upper armBack of the arm. Mounjaro and Zepbound: another person gives the injection here.
- 2AbdomenAt least 2 in (5 cm) from the belly button. Rotate the spot with each dose.
- 3ThighFront of the thigh. The semaglutide and tirzepatide labels report similar exposure at all three areas.
Section 2 of each label: the sentence a prescriber reads
The Ozempic label (Section 2.1, via DailyMed, accessed 14 September 2026) reads: "Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region." The same subsection says that with insulin the two are given as separate injections, never mixed, and that "it is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other."
The Wegovy label (Section 2, via DailyMed, accessed 14 September 2026) reads: "Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification." The next bullet is "Rotate injection sites with each dose." That clause about changing the site without a dosage modification is the label's own statement that the site is not a dosing variable, and it recurs on the liraglutide labels: Saxenda (Section 2) and Victoza (Section 2.3) both say "No dosage adjustment is needed if changing the injection site and/or timing."
The two Eli Lilly tirzepatide labels phrase the third area differently. Mounjaro (Section 2.2): "Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose." Zepbound (Section 2): "Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose." Trulicity (Section 2.4) keeps the plain form — "Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose." — and reserves the second-person condition for its IFU. Mounjaro, Victoza and Trulicity carry the same insulin sentence as Ozempic.
The Bydureon BCise label (Section 2, FDA accessdata) differs in wording only: "a subcutaneous injection in the abdomen, thigh, or upper arm region. Advise patients to use a different injection site each week when injecting in the same region." Eight brand-name labels, three areas, one route. None ranks the areas, recommends one over another, or ties an area to a dose.
Rotation: what each label says, and the same-area-versus-same-spot distinction
"Rotate injection sites with each dose" is a standalone bullet on the Wegovy, Mounjaro, Zepbound and Trulicity labels. Ozempic and Bydureon BCise say the same thing to the prescriber: a different injection site each week when injecting in the same region. Saxenda and Victoza are the only two that give a reason — "Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis [see Adverse Reactions (6.2)]" — and Section 6.2 of each liraglutide label lists cutaneous amyloidosis among postmarketing skin reactions (Saxenda Section 2 and 6.2; Victoza Section 2.3 and 6.2, accessed 14 September 2026).
The Medication Guides for Ozempic, Wegovy, Saxenda and Victoza carry the bullet "Change (rotate) your injection site with each injection. Do not use the same site for each injection." Zepbound's is the fullest: "Change (rotate) your injection site with each weekly injection. You may use the same area of your body but be sure to choose a different injection site in that area. Do not use the same site for each injection."
The Instructions for Use draw the line between area and spot explicitly. Wegovy IFU (Step 2, revised November 2025): "You may inject in the same body area each week, but make sure it is not in the same spot each time." Mounjaro and Zepbound single-dose pen IFUs (Step 1, revised April 2026) and the Trulicity pen IFU: "Change (rotate) your injection site each week. You may use the same area of your body but be sure to choose a different injection site in that area." Victoza pen IFU (Step H): "Change (rotate) your injection sites within the area you choose for each dose." Ozempic prefilled-syringe IFU (approved 05/2026): "Avoid using the exact same spot as the last time between injections."
The Mounjaro and Zepbound vial IFUs (revised April 2026) add a second reason for rotating: "to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites." That is the label saying why, in its own words. What no label gives is a rotation pattern, a number of spots per area or an order to move through; the how-to on rotating sites is about recording whatever pattern you and your prescriber settle on, not inventing one.
Does absorption differ by site? What Section 12.3 states, label by label
The labels address this directly, and across all seven marketed products the answer is that the site does not change exposure in a way the label treats as meaningful. Ozempic (Section 12.3, Absorption, accessed 14 September 2026): "Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm." Wegovy (Section 12.3): "Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm." Mounjaro and Zepbound (Section 12.3, each): "Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm." In each case the sentence sits beside the product's absolute bioavailability figure, which the per-product pages for Ozempic, Wegovy, Mounjaro and Zepbound quote in full.
Trulicity (Section 12.3, revised 03/2026) puts it statistically: "Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide."
The two liraglutide labels are the only ones that print a number. Victoza (Section 12.3, revised 10/2025): "AUC0-∞ was equivalent between upper arm and abdomen, and between upper arm and thigh. AUC0-∞ from thigh was 22% lower than that from abdomen. However, liraglutide exposures were considered comparable among these three subcutaneous injection sites." Saxenda (Section 12.3, revised 06/2026) keeps the conclusion and drops the figure: "Liraglutide exposures were considered similar among three subcutaneous injection sites (upper arm, abdomen, and thigh)." The Victoza and Saxenda pages carry the surrounding pharmacokinetics.
The Bydureon BCise label makes no statement about exposure by site; its Section 12.3 describes the extended-release microsphere's release over weeks and says nothing about the abdomen, thigh or arm (FDA accessdata, revised 05/2025). This page does not infer one. The practical reading of all of the above is the one the Wegovy, Saxenda and Victoza labels state in Section 2 themselves: the site can be changed without a dosage modification. It is not a reason to choose an area, and no label presents it as one.
The Instructions for Use: the site step, who injects the upper arm, and skin the IFU says to avoid
The IFU is where the labels stop agreeing word for word, because each is written for a specific device. The Wegovy single-dose pen IFU (Step 2, Choose your injection site, revised November 2025): "Your healthcare provider can help you choose the injection site that is best for you. You may inject into your upper leg (front of the thighs), lower stomach (keep 2 inches away from your belly button) or upper arm. Do not inject into an area where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks." The Wegovy FlexTouch IFU (revised 06/2026) lists the same areas and the same distance. The Wegovy prefilled-syringe IFU, bundled in the same 06/2026 label, lists the same three areas but conditions the third: "Back of upper arm (only with help from someone else)." Wegovy's troubleshooting section is the only place in any of these documents that expresses a site preference, and only for a pen that will not inject: "change to a more firm injection site, such as upper leg, or upper arm".
The Mounjaro and Zepbound single-dose pen IFUs (Step 1, revised April 2026): "Your healthcare provider can help you choose the injection site that is best for you. You or another person can inject the medicine in your stomach (abdomen) or thigh. Another person should give you the injection in the back of your upper arm." The Trulicity single-dose pen IFU puts the rotation sentence first and then: "You may inject the medicine into your stomach (abdomen) or thigh. Another person should give you the injection in the back of your upper arm." The Mounjaro and Zepbound KwikPen IFUs (Step 10, revised January 2026) add the belly-button distance — "at least 2 inches from the belly button" — and the vial IFUs (revised April 2026) add the skin to avoid: "Do not inject where the skin has pits, is thickened, or has lumps. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin."
The Novo Nordisk daily pens are sparer. The Saxenda pen IFU (Step 4) says "Choose your injection site" and "Insert the needle into your skin as your healthcare provider has shown you", with the areas appearing only on the IFU's body-diagram figure rather than in its text. The Victoza pen IFU (Step H) names them: "stomach (abdomen), thigh, or upper arm (only if caregiver administered)." The Ozempic pen IFU (revised June 2026) has no site list at all; its Step 4 says "Choose your injection site" and "Insert the needle into your skin as your healthcare provider has shown you", and the three areas appear in the Ozempic Medication Guide. The newer Ozempic prefilled-syringe IFU lists them: "Stomach area (abdomen) at least 2 inches from the belly button. Thighs. Back of upper arm (only with help from someone else)." Read across the IFUs, then, the second-person condition for the upper arm is not a Lilly-only feature: the Victoza pen IFU and the Ozempic and Wegovy prefilled-syringe IFUs carry it too, and it is only in Section 2 of the prescribing information that the split follows the manufacturer.
This page reproduces the site step and stops; the remaining steps are the IFU's to give for the exact pen in your hand, and the used pens page covers what the labels say about disposal.
What the labels do not say, and what is worth writing down
Three things a reader might expect are absent from all eight labels. None ranks the abdomen, thigh or upper arm or recommends one for a first injection, a body type or fewer side effects. None gives a rotation order, a number of spots per area or a minimum distance between consecutive spots; the only distance any label states is the 2 inches from the belly button. And none links site choice to dose.
What the labels do record is how often injection sites reacted in trials, and those figures belong to the product, not the site. Section 6.1 of the Ozempic label reports injection site reactions in 0.2% of Ozempic-treated patients in placebo-controlled trials; Wegovy reports 1.4% versus 1% on placebo in adult weight-reduction trials; Mounjaro reports 3.2% versus 0.4% on placebo in the adult placebo-controlled pool; Victoza reports approximately 2%; Saxenda's Table 2 lists injection site reaction at 13.9% versus 10.5% on placebo; and the Bydureon BCise label reports injection site reactions, including nodules, in 23.9% of treated patients in two 28-week trials, with a Section 5.9 warning on serious injection-site reactions that no other label in this set carries (Section 6.1 of each label, accessed 14 September 2026).
That is the one place a record helps. A site reaction is something the labels tell patients to report, and a report is more useful with a date and a location attached. GLP-1 Tracker, a free iPhone app that stores what you enter on your device, logs each dose with its date and the site you tapped on a body map, so "left thigh, three weeks ago" is a lookup rather than a guess; the injection site tracker page shows what that looks like. The app does not choose a site, suggest a rotation or interpret a reaction. If a spot is tender, bruised, red, hard, lumpy or thickened — the words the Wegovy and Mounjaro IFUs use — the IFU says not to inject there, and the person to tell is your prescriber or pharmacist, with the dated record in front of you.
Frequently asked questions
Where do the FDA labels say to inject a GLP-1?
In the abdomen, thigh or upper arm, subcutaneously. Section 2 of the Ozempic, Wegovy, Saxenda, Victoza and Trulicity labels prints exactly those three areas, and the Mounjaro and Zepbound labels print the same three with the upper arm assigned to another person. The Medication Guide for each product repeats the areas and adds that the product is not to be injected into a muscle or a vein. No label ranks the three areas or recommends one over another.
Do all GLP-1 labels say to rotate injection sites?
Yes. Wegovy, Mounjaro, Zepbound and Trulicity print the bullet Rotate injection sites with each dose. Ozempic and Bydureon BCise instruct prescribers to have patients use a different injection site each week when injecting in the same region. Saxenda and Victoza say to rotate within the same region in order to reduce the risk of cutaneous amyloidosis, and cross-reference their Section 6.2. Every Medication Guide adds: do not use the same site for each injection.
Does a GLP-1 absorb differently from the abdomen, thigh or arm?
According to the labels, not in a way they treat as meaningful. Section 12.3 of the Ozempic, Wegovy, Mounjaro and Zepbound labels states that similar exposure was achieved with subcutaneous administration in the abdomen, thigh or upper arm. The Trulicity label states the site had no statistically significant effect on exposure. The Victoza label reports AUC from the thigh 22% lower than from the abdomen but concludes that exposures were comparable across the three sites, and the Saxenda label calls them similar. The Bydureon BCise label makes no statement about site.
Which GLP-1 labels say the upper arm should be injected by someone else?
In Section 2 of the prescribing information, only the Mounjaro and Zepbound labels: both say another person should inject in the back of the upper arm, and the Mounjaro, Zepbound and Trulicity Instructions for Use repeat it, although Trulicity's own Section 2.4 lists the upper arm without that condition. In the Instructions for Use the condition is not tirzepatide-only. Among the Novo Nordisk products, the Victoza pen IFU lists the upper arm only if caregiver administered, and the Ozempic prefilled-syringe IFU and the Wegovy prefilled-syringe IFU both say only with help from someone else. The Wegovy single-dose pen and FlexTouch IFUs and the Ozempic and Saxenda Medication Guides list the upper arm without that condition.
Can I inject in the same body area every week?
The labels say yes, as long as it is not the same spot. The Wegovy IFU says you may inject in the same body area each week but make sure it is not in the same spot each time. The Mounjaro, Zepbound and Trulicity IFUs say you may use the same area of your body but be sure to choose a different injection site in that area. The Ozempic label says the same thing to the prescriber: a different injection site each week when injecting in the same body region. Which area, and what pattern within it, is between you and your prescriber.
What skin do the Instructions for Use say to avoid?
The Wegovy IFU says not to inject into an area where the skin is tender, bruised, red or hard, and to avoid areas with scars or stretch marks. The Mounjaro and Zepbound vial IFUs say not to inject where the skin has pits, is thickened or has lumps, or where it is tender, bruised, scaly or hard, or into scars or damaged skin. The Wegovy, Mounjaro and Zepbound IFUs and the Ozempic prefilled-syringe IFU also say to keep 2 inches from the belly button when using the abdomen. The Saxenda and Ozempic pen IFUs list no skin conditions and defer to what your healthcare provider has shown you.
What do the labels say about injecting a GLP-1 and insulin in the same area?
Section 2 of the Ozempic, Mounjaro, Victoza and Trulicity labels says to administer the two as separate injections, never to mix them, and that it is acceptable to inject the product and insulin in the same body region provided the injections are not adjacent to each other. The Medication Guides put it as: you may give both in the same body area, such as your stomach area, but not right next to each other. The Mounjaro vial IFU adds a general instruction not to inject in the same injection site used for other medicines. Whether you use insulin at all is a prescriber question.
Does this page tell me which site to use?
No. It reproduces what eight FDA labels say about injection sites, names the section for each quotation, and stops. The labels themselves say the healthcare provider can help you choose the site that is best for you. If you are unsure which area to use, whether a spot is suitable, or what a reaction at a site means, the answer comes from your prescriber or pharmacist with the product's own Instructions for Use open, not from a website.
Keep the site record; leave the site choice to your prescriber
GLP-1 Tracker is a free iPhone app that logs each dose with its date and the site you tapped on a body map, plus weight, meals and a dated note when a spot looks or feels different, stored on your device. It organises what you enter so rotation is a lookup rather than a memory; it never picks a site or interprets a reaction.
Reading on a desktop? Scan to open it on your iPhone.apps.apple.com/app/id6765520636
This page is for general education only and is not medical advice, diagnosis or treatment. GLP-1 Tracker is a tracking tool, not a medical device. Always consult your healthcare provider about your medication, dosing and health decisions. Brand names are trademarks of their respective owners and are not affiliated with this app.